ArticleOncology reports2026
Exploring the role of disulfidptosis‑related signatures in immune microenvironment, prognosis and therapeutic strategies of cholangiocarcinoma.
Article in Oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cholangiocarcinoma (CCA) is an aggressive malignancy with poor prognosis and a limited number of treatments is available. Disulfidptosis, a newly identified form of cell death triggered by disulfide bond accumulation during glucose deprivation, may influence cancer progression but its role in CCA is poorly understood. The present study investigated disulfidptosis‑related genes (DRGs) and their impact on CCA prognosis and immune modulation. Differential expression analysis of 100 DRGs using RNA sequencing data from The Cancer Genome Atlas and EMBL‑EBI identified 74 dysregulated genes in CCA. Unsupervised clustering stratified patients with CCA into two distinct subtypes (Subs): i) SubA; and ii) SubB. A four‑gene prognostic signature was developed using least absolute shrinkage and selection operator regression and validated via Kaplan‑Meier survival analysis and receiver operating characteristic curves. Immune infiltration and tumor microenvironment were evaluated using Cell‑type Identification by Estimating Relative Subsets of RNA Transcripts, Estimation of Stromal and Immune cells in Malignant Tumor tissues using Expression data and single‑sample Gene Set Enrichment Analysis. Functional assays, including small interfering RNA knockdown of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.